92 results on '"Anwer, Faiz"'
Search Results
2. The TACTUM23 Study: Access to Cellular Therapies in Multiple Myeloma: Perspectives of Treating Versus Referring Physicians in 2023
3. Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Not Meeting the Karmma-1 Trial Eligibility Criteria: A Real-World Multicenter Study from the US Myeloma Innovations Research Collaborative (USMIRC)
4. A Multicenter Experience: Duration of Mandatory CRS and Icans Monitoring for Myeloma and Lymphoma CAR-T Recipients
5. Impact of Frailty on Outcomes after CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma
6. Neighborhood Socioeconomic Disadvantage and Distance from Treatment Center Do Not Impact Survival Outcomes of Patients with Non-Hodgkin's Lymphoma (NHL) and Multiple Myeloma (MM) Treated with CAR T-Cell Therapies.
7. Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience from the US Myeloma Innovations Research Collaborative (USMIRC)
8. Outcomes of BCMA-Directed Chimeric Antigen Receptor T-Cell (CART) Therapy and Teclistamab in Patients with Relapse-Refractory Multiple Myeloma with Extramedullary Disease: A Real-World Experience of the US Myeloma Innovations Research Collaborative (USMIRC)
9. Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience
10. Impact of Frailty on Outcomes after Chimeric Antigen Receptor T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma
11. P-330 The third-generation genetic engineered mouse model of late-stage multiple myeloma
12. POSTER: MM-255 Advances in CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-analysis of Clinical Trials in the Last Two Years
13. P-256 Initial report of a single institution experience with teclistamab for relapsed or refractory multiple myeloma including prior BCMA
14. MM-255 Advances in CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis of Clinical Trials in the Last Two Years
15. P-320 Iberdomide (IBER) plus dexamethasone (DEX) in patients with relapsed/refractory multiple myeloma (RRMM): a safety analysis from the CC-220-MM-001 trial
16. P-465 Global disparities in multiple myeloma: examining adverse events and drug toxicity trends
17. Clinical Efficacy of Retreatment With Venetoclax-Based Therapy in Relapsed-Refractory t(11;14) Multiple Myeloma
18. Efficacy and tolerability of isocitrate dehydrogenase inhibitors in patients with acute myeloid leukemia: A systematic review of clinical trials
19. Total Body Irradiation Versus Chemotherapy Conditioning in Pediatric Acute Lymphoblastic Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant: A Systematic Review and Meta-Analysis
20. Ethical Challenges in CAR-T slot allocation
21. Advancements and future trends of immunotherapy in light-chain amyloidosis
22. Evaluation of Major Adverse Cardiac Events (MACE) and Arrhythmias in Patients with Large B-Cell Lymphoma Undergoing Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Utility of Baseline Cardiac Biomarkers
23. The Characteristics of Multiple Myeloma Patients Referred for CAR T-Cell Therapy
24. Incidence of Venous Thromboembolism in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplant
25. Factors That Predict Early Relapse Post Autologous Hematopoietic Cell Transplant in Multiple Myeloma Patients
26. Analysis of Factors That Predict Progression Free and Overall Survival Post Autologous Hematopoietic Cell Transplant in Multiple Myeloma Patients
27. Outcomes of CMV Infection in the Setting of Gastrointestinal Graft Vs. Host Disease in the Era of Pre-Emptive and Prophylactic Antiviral Therapy
28. Infectious Complications Following CAR T-Cell Therapy in Patients with Relapsed and Refractory Multiple Myeloma
29. EFFICACY AND SAFETY OF THERAPEUTIC VERSUS PROPHYLACTIC ANTICOAGULATION IN PATIENTS WITH COVID-19 INFECTION: A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS
30. P-279: Efficacy, safety, and pharmacokinetics of iberdomide plus dexamethasone in patients with relapsed/refractory multiple myeloma by renal function: a subgroup analysis of the CC-220-MM-001 trial
31. P-007: Proposed clinical factors scoring system for chimeric antigen receptor T-cell (CAR T) patient selection in relapsed and refractory multiple myeloma (RRMM)
32. NS-005: The Cleveland Clinic Survivor Care Program Model for patients living with multiple myeloma and plasma cell disorders
33. Evidence-based recommendations for induction and maintenance treatment of newly diagnosed transplant-ineligible multiple myeloma patients
34. P-134: Clinical characteristics and long-term outcomes of patients with POEMS syndrome: a large academic center’s experience
35. Efficacy of Monoclonal Antibodies in Adult Acute Lymphoblastic Leukemia: A Systematic Review
36. The Association of Pre-Transplant Adiposity with Autologous Hematopoietic Stem Cell Transplantation Outcomes in Lymphoma
37. Validation of Pre-Treatment Modified Easix Score As a Predictor of Cytokine Release Syndrome Related to Anti CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
38. The Impact of Atrial Fibrillation on hospitalization Outcomes for Patients With Chronic Lymphocytic Leukemia Using the National Inpatient Sample Database
39. Emerging Targets and Cellular Therapy for Relapsed Refractory Multiple Myeloma: A Systematic Review
40. Primary Mediastinal B-Cell Lymphoma: A 2021 Update on Genetics, Diagnosis, and Novel Therapeutics
41. Management of Relapsed Hairy Cell Leukemia: A Systematic Review of Novel Agents and Targeted Therapies
42. MM-392: Belantamab Mafodotin (Belamaf; GSK2857916) US Expanded Access Program (EAP) for Heavily Pre-Treated Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Characteristics
43. Poster: MM-392: Belantamab Mafodotin (Belamaf; GSK2857916) US Expanded Access Program (EAP) for Heavily Pre-Treated Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Characteristics
44. Progress in research: Daratumumab improves treatment outcomes of patients with AL amyloidosis
45. Vaccine responses in patients with chronic lymphocytic leukemia on treatment with Bruton Tyrosine Kinase Inhibitors: a focused review
46. Impact of Acquired Thrombocytopenia on Cardiovascular Outcomes in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis
47. Allogeneic hematopoietic stem cell transplantation in aplastic anemia: current indications and transplant strategies
48. Comparison of the Prognostic Value of Risk Assessment Tools in Allogeneic Hematopoietic Cell Transplantation
49. Decreased Incidence of Graft-Versus-Host Disease with Post-Transplant Cyclophosphamide in HLA-Matched Allogeneic Hematopoietic Cell Transplantation
50. Resource Utilization and Factors Prolonging Hospitalization for Patients with Refractory and Relapsed Large B-Cell Lymphoma Receiving Tisagenlecleucel Versus Axicabtagene Ciloleucel
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.